- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00004056
Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia
Treatment of Newly Diagnosed Childhood AML Using a Timed-Sequential Remission Induction and Consolidation Followed by Single Dose Melphalan With Peripheral Stem Cell Rescue: A POG Pilot Study
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells.
PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy followed by melphalan and peripheral stem cell transplantation in treating children who have newly diagnosed acute myeloid leukemia that has not been treated previously.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
OBJECTIVES: I. Determine the feasibility and toxicity of timed sequential remission induction and consolidation in children with newly diagnosed acute myeloid leukemia. II. Determine the feasibility and toxicity of a single high dose of melphalan with peripheral blood stem cell rescue following an intense timed sequential induction and consolidation in these children.
OUTLINE: This is a multicenter study. Remission induction: Patients receive daunorubicin IV over 15 minutes on days 1-3, cytarabine IV continuously on days 1-7, oral thioguanine daily on days 1-7, and cytarabine intrathecally (IT) on day 1. Cytarabine IV over 3 hours is administered every 12 hours on days 10-12. Filgrastim (G-CSF) is administered IV or subcutaneously (SQ) beginning on day 13 and continuing until blood counts recover. On approximately day 28, patients undergo a bone marrow aspirate and biopsy to assess response. Patients who have attained an M1 or M2a status proceed to consolidation or, if a 5/5 or 6/6 HLA matched sibling donor is available, proceed to allogeneic bone marrow transplantation. Patients with greater than 25% blasts go off study. Consolidation 1: Patients receive daunorubicin IV over 15 minutes on days 1 and 2, cytarabine IV over 3 hours every 12 hours on days 1, 2, 8, and 9, and asparaginase on days 2 and 9. G-CSF IV or SQ begins on day 10 and continues until blood counts recover. Consolidation 2: Patients receive cytarabine IV over 3 hours every 12 hours on days 1, 3, and 5. G-CSF IV or SQ begins on day 6 and continues until blood counts recover. Peripheral blood stem cells (PBSC) are collected after the second course of consolidation. Consolidation 3: Treatment is repeated as in consolidation 1. Patients who remain in morphologic remission after consolidation 3 proceed with therapy. Patients receive melphalan IV over 30 minutes on day -2, then PBSC are reinfused on day 0. G-CSF IV or SQ begins on day 1 and continues until blood counts recover. Patients are followed every 6 months for 4 years and then annually thereafter.
PROJECTED ACCRUAL: A total of 20-30 patients will be accrued for this study within 8 months.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 1
Kontakter och platser
Studieorter
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35294
- University of Alabama Comprehensive Cancer Center
-
-
Arizona
-
Tucson, Arizona, Förenta staterna, 85724
- Arizona Cancer Center
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Palo Alto, California, Förenta staterna, 94304
- Lucile Packard Children's Hospital at Stanford
-
San Diego, California, Förenta staterna, 92123-4282
- Children's Hospital and Health Center
-
-
Florida
-
Jacksonville, Florida, Förenta staterna, 32207
- Nemours Children's Clinic
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Emory University Hospital - Atlanta
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60614
- Children's Memorial Hospital, Chicago
-
-
Maine
-
Scarborough, Maine, Förenta staterna, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21231
- Johns Hopkins Oncology Center
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Massachusetts General Hospital Cancer Center
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48201
- Children's Hospital of Michigan
-
-
Missouri
-
Saint Louis, Missouri, Förenta staterna, 63104
- Cardinal Glennon Children's Hospital
-
-
New Jersey
-
Hackensack, New Jersey, Förenta staterna, 07601
- Hackensack University Medical Center
-
Hackensack, New Jersey, Förenta staterna, 07601
- Tomorrows Children's Institute
-
-
New York
-
New York, New York, Förenta staterna, 10029
- Mount Sinai School of Medicine
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75235-9154
- Simmons Cancer Center - Dallas
-
Fort Worth, Texas, Förenta staterna, 76104
- Cook Children's Medical Center - Fort Worth
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Midwest Children's Cancer Center
-
-
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- Montreal Children's Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS: Histologically proven, previously untreated primary acute myeloid leukemia (AML) Isolated granulocytic sarcoma (myeloblastoma) allowed Patients with cytopenias and bone marrow blasts greater than 5% but less than 30% eligible only if there is karyotypic abnormality characteristic of de novo AML (t(8;21), inv16, t(9;11), etc.) OR unequivocal presence of megakaryoblasts No acute promyelocytic leukemia (M3) No Down syndrome
PATIENT CHARACTERISTICS: Age: 21 and under Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 3 times upper limit of normal Renal: Creatinine no greater than 1.5 mg/dL Uric acid no greater than 8.0 mg/dL Cardiovascular: Cardiac function normal by echocardiogram Pulmonary: No uncontrolled, life threatening pneumonia Other: No uncontrolled, life threatening sepsis or meningitis Not pregnant Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY: No prior therapy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Chemo + STEM cell
See detailed description.
|
Andra namn:
Andra namn:
Andra namn:
Andra namn:
Andra namn:
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Feasibility and toxicity of an intensive regimen that uses timed-sequential therapy
Tidsram: Length of study
|
To determine the feasibility and toxicity of an intensive regimen that uses timed-sequential therapy as a strategy for both remission induction and consolidation of newly diagnosed children with AML.
|
Length of study
|
Feasibility and toxicity of a single high dose of melphalan with peripheral stem cell rescue
Tidsram: Length of study
|
To test the feasibility and toxicity of a single high dose of melphalan with peripheral stem cell rescue following an intense timed-sequential induction and consolidation.
|
Length of study
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Make observations regarding PCR evidence of Minimal Residual Disease
Tidsram: Length of study
|
To make observations regarding PCR evidence of Minimal Residual Disease in patients with relevant specific translocations who obtain a clinical remission.
|
Length of study
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Studiestol: Craig A. Hurwitz, MD, Maine Children's Cancer Program at Barbara Bush Children's Hospital
Publikationer och användbara länkar
Allmänna publikationer
- Hurwitz CA, Chang M, Graham M, et al.: Timed-sequential remission induction and intensification followed by stem cell rescue for childhood AML -a POG pilot study. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1553, 2002.
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
- akut erytroleukemi hos barn (M6)
- akut megakaryocytisk leukemi hos barn (M7)
- akut minimalt differentierad myeloid leukemi (M0)
- obehandlad akut myeloid leukemi hos barn och andra myeloida maligniteter
- akut myeloblastisk leukemi i barndom utan mognad (M1)
- akut myeloblastisk leukemi hos barn med mognad (M2)
- akut myelomonocytisk leukemi hos barn (M4)
- Akut monoblastisk leukemi hos barn och akut monocytisk leukemi (M5)
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Leukemi
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Anti-infektionsmedel
- Antivirala medel
- Enzyminhibitorer
- Antimetaboliter, antineoplastiska
- Antimetaboliter
- Antineoplastiska medel
- Immunsuppressiva medel
- Immunologiska faktorer
- Antineoplastiska medel, Alkylering
- Alkyleringsmedel
- Myeloablativa agonister
- Topoisomeras II-hämmare
- Topoisomerasinhibitorer
- Adjuvans, immunologiska
- Antibiotika, antineoplastiska
- Lenograstim
- Melphalan
- Cytarabin
- Daunorubicin
- Asparaginas
- Tioguanin
Andra studie-ID-nummer
- 9822
- POG-9822
- CDR0000067253
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Leukemi
-
Massachusetts General HospitalCelgene CorporationAvslutadAkut myelogen leukemi | Akut myeloid leukemi (AML) | Akut myelocytisk leukemi | Akut granulocytisk leukemi | Akut icke-lymfocytisk leukemiFörenta staterna
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for...RekryteringRefraktär leukemi | Återfallande leukemi | Akut myeloid leukemi, barndomKina
-
GlaxoSmithKlineAvslutadLeukemi, Myelocytisk, AkutFörenta staterna, Australien, Kanada
-
Hybrigenics CorporationOkändAkut myelogen leukemiFörenta staterna, Frankrike
-
Betta Pharmaceuticals Co., Ltd.Har inte rekryterat ännuAkut Myeloid Leukemi LeukemiKina
-
Beijing Boren HospitalRekryteringAkut myeloid leukemi | Refraktär Akut Myeloid Leukemi | Återfall leukemiKina
-
Center for International Blood and Marrow Transplant...National Marrow Donor Program; St. Baldrick's FoundationAktiv, inte rekryterandeAkut myelogen leukemiFörenta staterna
-
Massachusetts General HospitalAvslutad
-
Sidney Kimmel Comprehensive Cancer Center at Johns...AvslutadAkut lymfoblastisk leukemi | Akut myelogen leukemi (AML) | Akut lymfatisk leukemi (ALL) | Akut promyelocytisk leukemi (APL)Förenta staterna
-
Kinex Pharmaceuticals Inc.AvslutadAkut myelogen leukemiFörenta staterna
Kliniska prövningar på asparaginas
-
medac GmbHAvslutadAkut lymfoblastisk leukemiNederländerna
-
medac GmbHAvslutadAkut lymfoid leukemiTyskland, Nederländerna
-
Jazz PharmaceuticalsAvslutadAkut lymfoblastisk leukemi | Lymfoblastiskt lymfomFörenta staterna, Kanada
-
Phoenix Children's HospitalJazz Pharmaceuticals; Fisher BioservicesInte längre tillgängligAkut lymfoid leukemi | Leukemi, akut lymfoblastisk
-
ERYtech PharmaCentre Leon BerardAvslutadAkut lymfoblastisk leukemiFrankrike
-
medac GmbHSyneos HealthRekryteringAkut B-cells lymfoblastisk leukemiBrasilien
-
Nordic Society for Pediatric Hematology and OncologyDanish Child Cancer Foundation; Medac, Hamburg, GermanyOkänd
-
Fudan UniversityAvslutad
-
ERYtech PharmaAvslutadAkut lymfoblastisk leukemi | Lymfoblastiskt lymfomFörenta staterna
-
Children's Oncology GroupRekryteringLymfoblastiskt lymfom | B Akut lymfoblastisk leukemi | B Akut lymfoblastisk leukemi med t(9;22)(q34.1;q11.2); BCR-ABL1 | T Akut lymfoblastisk leukemi | Blandad fenotyp Akut leukemi | B Akut lymfoblastisk leukemi, BCR-ABL1-liknandeFörenta staterna, Kanada